Abstract 284TiP
Background
Landmark trials have established a survival benefit for novel hormonal agents (NHA) added to androgen deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC). Yet, there is a significant medical need to expand therapeutic options, especially for pts with high-risk mHSPC who experience poorer outcomes. Abemaciclib is an oral selective inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6) dosed on a continuous schedule and approved for the treatment of node-positive high-risk early-stage and advanced or metastatic HR+, HER2− breast cancer. Analogous to the estrogen receptor signaling pathway in breast cancer, there is evidence that the androgen receptor axis activates CDK4/6 to sustain prostate cancer cell proliferation, and upregulation of cyclin D1 is a potential mechanism of resistance to NHA therapy. In preclinical models, abemaciclib induces cell cycle arrest and inhibition of prostate tumor growth.
Trial design
CYCLONE 3 is a global, randomized, double-blind, placebo-controlled study evaluating the addition of abemaciclib to abiraterone+prednisone (AP) in pts with high-risk mHSPC. Approximately 900 pts with high-risk mHSPC defined by ≥4 bone metastases and/or visceral disease will be randomised in a 1:1 ratio to the AP + abemaciclib or AP + placebo arm. Up to 3 months of ADT prior to randomization is permitted; prior docetaxel for mHSPC is excluded. Pts who has not undergone orchiectomy will continue ADT. Stratification factors are de novo mHSPC and visceral metastases. Primary endpoint is investigator-assessed radiographic progression-free survival (rPFS). Key secondary endpoints include rPFS assessed by blinded independent central review, castration-resistant prostate cancer-free survival, overall survival, time to pain progression, safety and pharmacokinetics. Approximately 270 sites across 24 countries are participating, including in Asia. Updated from abstract previously presented at European Society for Medical Oncology (ESMO) 2022, FPN (Final Publication Number): 2189, Rana McKay et al. Reused with permission.
Clinical trial identification
NCT05288166.
Editorial acknowledgement
Legal entity responsible for the study
Eli Lilly and Company.
Funding
Eli Lilly and Company.
Disclosure
N. Matsubara: Other, Personal and Institutional, Advisory Role, Honoraria, Speakers’ bureau, Research funding: Janssen, MSD; Other, Personal and Institutional, Research Funding, Honoraria: Taiho; Other, Personal and Institutional, Advisory Role, Research funding: Bayer, Roche; Other, Personal and Institutional, Advisory Role, Speakers’ bureau: Sanofi; Other, Personal and Institutional, Speaker’s Bureau: AstraZeneca. N. Agarwal: Other, Personal and Institutional, Advisory Role: Eli Lilly & Company, Janssen, Pfizer, Bayer, Amgen, Novartis, Bristol Myers Squibb, Astellas Pharma, AstraZeneca, ORIC Pharmaceuticals, Nektar, Pharmacyclics, Foundation Medicine, Eisai, AVEO; Other, Personal, Advisory Role: Calithera Biosciences, MEI Pharma, Gilead Sciences, Takeda. M.R. Smith: Other, Personal and Institutional, Advisory Role, Honoraria, Research Funding: Astellas Pharma, Bayer, Pfizer, Janssen, Lilly; Other, Personal and Institutional, Research Funding: Arvinas. R.R. McKay: Financial Interests, Personal, Research Funding, Consulting or Advisory Role: Bayer, Pfizer, Tempus; Financial Interests, Personal, Advisory Role: Astellas Medivation, AstraZeneca, Aveo, Bristol Myers Squibb, Calithera, Caris, Dendreon, Exelixis, Janssen, Merck, Myovant, Novartis, Sanofi. T. Todenhöfer: Financial Interests, Personal, Advisory Role: Eli Lilly and Company, Janssen, Pfizer, Bayer, Novartis, Amgen, Bristol Myers Squibb, Astellas Pharma, AstraZeneca, Roche, Ipsen, Basilea. J.M. Piulats Rodriguez: Financial Interests, Personal, Advisory Role: Pfizer, Janssen, Bristol Myers Squibb, Merck, Roche, AstraZeneca, Astellas Pharma, Clovis Oncology, VCN Biosciences, Incyte, EMD Serono, BeiGene. K.L. Chung, D. Heirich, S. Sherwood, C. Schaverien, N. Fasnacht, A. Lithio, K. Nacerddine: Financial Interests, Personal, Other, Employee and Shareholder: Eli Lilly and Company. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract